Amgen to buy Horizon Therapeutics in $26.4 billion deal
Amgen is spending more than $26 billion to dive deeper into rare disease treatments with a deal for drugmaker Horizon Therapeutics.
The biotech drug developer said Monday that it will pay $116.50 in cash for each share of Horizon, which makes a thyroid eye disease treatment that generated more than $1 billion in its first full year on the market.
The deal offers Amgen another chance to build its portfolio of rare-disease treatments after it closed in October a roughly $3.7 billion acquisition of ChemoCentryx, which focuses on autoimmune disease drugs.
Horizon Therapeutics PLC, based in Dublin, Ireland, develops potential treatments for rare, autoimmune and severe inflammatory diseases. Its bestseller, Tepezza, is only approved
in the United States and treats eye bulging and double vision from thyroid eye disease.
U.S. regulators approved Tepezza in early 2020 as the first treatment for thyroid
eye disease. The drug’s sales more than doubled last year to $1.67 billion. That’s about half of the company’s total sales of $3.23 billion.
Amgen leaders told analysts on a Monday morning
conference call that they intend to expand the drug’s use globally. Scientists also are working to develop and easier-to-use injectable version of the drug, which is given by IV.
Amgen Chairman and CEO Robert Bradway said the deal gives his company a “strong platform” to expand into rare disease treatments, with many Horizon drugs still early in their life cycle.
Horizon also makes Krystexxa for uncontrolled gout. Sales of that treatment grew 39% last year to $565.5 million. Amgen officials said they expect their company’s long-standing history of working with rheumatologists will help that treatment’s sales grow.
Horizon also has a pipeline of additional potential treatments in mid-stage clinical testing and a possible therapy for the autoimmune disease myasthenia gravis in late-stage testing.
Amgen is facing competition for some of its key products like its autoimmune disease treatment Enbrel, so a Horizon takeover makes strategic sense, Mizuho Securities USA analyst Salim Syed said in a research note. He also said Horizon’s presence in Ireland, which has lower corporate tax rates than the United States, could help Amgen cut its tax bill.
Horizon said late last month that it had started “highly preliminary discussions” about an acquisition with three potential suitors: Amgen, the French drugmaker Sanofi, and Johnson & Johnson’s Janssen division.
Amgen had confirmed discussions were taking place and said that any offer it made for Horizon likely would be in cash.
The deal laid out Monday represents a premium of 48% to Horizon’s closing price of $78.76 before it made that late-November announcement.
Amgen said it expects the deal, which has an enterprise value of about $28.3 billion, to close in the first half of next year.